The phase 3 CLEAR trial, presented at the 2023 ASCO Annual Meeting, demonstrated that lenvatinib combined with pembrolizumab exhibited sustained superiority over sunitinib in overall and progression-free survival when used as a first-line treatment for advanced renal cell carcinoma. At about 50 months of median follow-up, risk of death was reduced by 21% with the combination treatment, and the overall survival rates for the combination treatment were better than sunitinib at 24, 36, and 48 months.
For more insights, a video featuring Dr. Thomas E. Hutson discussing the CLEAR trial can be found at www.ascopost.com/videos.
Reference: Goodman A. CLEAR Trial: Continued Survival Benefit With First-Line Lenvatinib Plus Pembrolizumab in Advanced Kidney Cancer. The ASCO Post. Published August 25, 2023. Accessed October 16, 2023. https://ascopost.com/issues/august-25-2023-supplement-genitourinary-oncology-almanac/continued-survival-benefit-with-first-line-lenvatinib-plus-pembrolizumab-in-advanced-kidney-cancer/
